In search of novel working mechanisms of proteasome inhibitors in multiple myeloma KU Leuven
Proteasome inhibitors (PIs) constitute one of the cornerstones of the treatment of multiple myeloma (MM), with bortezomib, carfilzomib and ixazomib approved for clinical use. However, MM still remains incurable, and almost all patients will eventually develop treatment-refractory disease. Moreover, there are currently no validated biomarkers to predict treatment response to PIs. Additionally, due to the relatively recent introduction of ...